Café

© 2026 Longbridge｜Terms of Service Privacy Policy

AstraZeneca, Daiichi Sankyo Breast Cancer Drug Wins NHS Access in England

CoinLive

Sep 16, 2026 at 11:15 PM

Women in England with an aggressive form of breast cancer will get access to an AstraZeneca Plc and Daiichi Sankyo Co. drug on the National Health Service after an agreement with the regulator, according to Bloomberg.

Source: CoinLive The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings

Feb 10, 2026 at 01:42 PMGlobal news you need to know before the U.S. stock market opens on Tuesday
Feb 10, 2026 at 08:30 AMAfter investing $18.5 billion to partner with Stone Group, AstraZeneca's earnings per share are expected to increase by …
Nov 11, 2025 at 01:51 PMConsolidating its position as the "largest heavyweight stock" in the UK market, pharmaceutical giant Astrazeneca's stock…
Jul 29, 2025 at 07:44 AMStrong sales of anti-cancer drugs, AstraZeneca's Q2 revenue increased by 12% year-on-year, exceeding expectations | Fina…

Related Stocks

AstraZeneca

USAZN

+2.00%

Daiichi Sankyo

USDSNKY

+3.92%

AstraZeneca PLC

UKAZN

LongbridgeAI